-

06:00:40 AM

IMGO Stock News

IMGO - Imago BioSciences Inc

05/16/22 8:00 AM

Nasdaq : IMGO

conferenceslow float

Imago BioSciences to Participate in Upcoming Investor Conferences

Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering and developing new medicines for the treatment of myeloproliferative neoplasms (MPNs), today announced that Hugh Young Rienhoff,

RHEA-AI

neutral

05/12/22 4:05 PM

Nasdaq : IMGO

earningslow float

Imago BioSciences Reports First Quarter 2022 Financial Results and Provides Recent Business Updates

- Completed Type C meeting with FDA to align on study design, study population, control group and primary endpoint for planned Phase 3 essential thrombocythemia (ET) study - Enrollment completed in Phase 2 trial of bomedemstat for treatment of ET - Additional data from Phase 2 trial of bomedemstat

RHEA-AI

neutral

05/12/22 8:00 AM

Nasdaq : IMGO

conferencesclinical triallow float

Imago BioSciences Announces Upcoming Presentations on Updated Data from Phase 2 Studies of Bomedemstat for the Treatment of Essential Thrombocythemia and Myelofibrosis at the 27th Congress of the European Hematology Association (EHA) for 2022

Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering and developing new medicines for the treatment of myeloproliferative neoplasms (MPNs) and other bone marrow diseases, today

RHEA-AI

neutral

05/09/22 8:00 AM

Nasdaq : IMGO

low float

Imago BioSciences Announces First Participant Dosed in Investigator-Sponsored Study of Bomedemstat in Combination with Atezolizumab in Small Cell Lung Cancer

Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering and developing new medicines for the treatment of myeloproliferative neoplasms (MPNs) and other bone marrow diseases, today

RHEA-AI

neutral

05/03/22 8:00 AM

Nasdaq : IMGO

clinical triallow float

Imago BioSciences Announces Completion of Enrollment in Phase 2 Clinical Study of Bomedemstat in Essential Thrombocythemia

Interim Data Update at European Hematology Association (EHA) meeting in June and Results from Completed Phase 2 Study Expected in Second Half of 2022 End-of-Phase 2 Meeting with U.S. Food and Drug Administration (FDA) Expected in Second Half of 2022 SOUTH SAN FRANCISCO, Calif., May 03, 2022

RHEA-AI

neutral

03/24/22 4:05 PM

Nasdaq : IMGO

earningslow float

Imago BioSciences Reports Fourth Quarter and Full Year 2021 Financial Results

Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs) and other bone marrow diseases, today reported

RHEA-AI

positive

03/23/22 4:05 PM

Nasdaq : IMGO

managementlow float

Imago BioSciences Appoints Michael Arenberg to Chief Operating and Business Officer

Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering new medicines for the treatment of

RHEA-AI

very positive

02/28/22 4:05 PM

Nasdaq : IMGO

conferenceslow float

Imago BioSciences to Participate in the Cowen 42nd Annual Health Care Conference

Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs), today announced that Hugh Y. Rienhoff, Jr., M.D.,

RHEA-AI

neutral

02/04/22 4:05 PM

Nasdaq : IMGO

conferenceslow float

Imago BioSciences to Participate in Guggenheim Healthcare Talks 2022 Oncology Conference

Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs), today announced that Hugh Y. Rienhoff, Jr., M.D., Imago’s

RHEA-AI

neutral

12/12/21 9:46 AM

Nasdaq : IMGO

clinical triallow float

Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Essential Thrombocythemia at ASH 2021

Imago BioSciences, Inc., a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms, today presented positive data from its ongoing global Phase 2 clinical study evaluating bomedemstat in patients with essential thrombocythemia. I am delighted with the progress we are making with this study...

RHEA-AI

neutral